Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics Revenue

Avalo Therapeutics had revenue of $1.45M in the twelve months ending March 31, 2024, down -91.64% year-over-year. In the year 2023, Avalo Therapeutics had annual revenue of $1.92M, a decrease of -89.34%.

• Revenue (ttm): $1.45M
• Revenue Growth: -91.64%
• P/S Ratio: 8.74
• Revenue / Employee: $76,316
• Employees: 19
• Market Cap: 12.68M USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	1.92M	-16.13M	-89.34%
Dec 31, 2022	18.05M	12.65M	234.40%
Dec 31, 2021	5.40M	-1.30M	-19.42%
Dec 31, 2020	6.70M	-51.35K	-0.76%
Dec 31, 2019	6.75M	-278.03K	-3.96%
Dec 31, 2018	7.03M	-20.78M	-74.73%
Dec 31, 2017	27.81M	26.66M	2,312.27%
Dec 31, 2016	1.15M	-	-
Dec 31, 2015	0	-	-
Dec 31, 2014	0	-	-
Dec 31, 2013	0	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.